<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543632</url>
  </required_header>
  <id_info>
    <org_study_id>RD1591</org_study_id>
    <nct_id>NCT02543632</nct_id>
  </id_info>
  <brief_title>PARACHUTE V PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE.</brief_title>
  <acronym>P5</acronym>
  <official_title>PARACHUTE V: PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE. A German Trial to Evaluate the Improvement in Quality of Life and Cardiac Output Following Implanting of the Parachute Implant System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioKinetix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioKinetix, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, post-market, non-randomized, nested-control, observational study
      of the CE marked CardioKinetix Parachute Implant System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, post-market, non-randomized, nested-control, observational study
      of the European Conformity Approved (CE marked) CardioKinetix Parachute Implant System. The
      primary objective is to establish quality-of-life and cardiac output benefit of the Parachute
      Implant of patients presenting with symptoms of heart failure due to ischemic heart disease.
      A maximum of 105 treated patients and approximately 25 control patients may be enrolled, with
      a maximum of 25 treated patients enrolled from any one center. The Primary Endpoint is an
      improvement of Quality of Life of patients treated with the Parachute Implant at 6 months
      compared to baseline using the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The
      Secondary Endpoint is an improvement in Stroke Volume Index (mL/m2) of patients treated with
      the Parachute Implant at post-procedure compared to pre-procedure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company closed
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>An improvement of Quality of Life of patients treated with the Parachute Implant at 6 months compared to baseline (day -1) using the Minnesota Living with Heart Failure (MLWHF) Questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume Index</measure>
    <time_frame>0 days (at implant)</time_frame>
    <description>An improvement in Stroke Volume Index (mL/m2) of patients treated with the Parachute Implant at post-procedure compared to pre-procedure.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <description>Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parachute Implant System</intervention_name>
    <description>The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.</description>
    <arm_group_label>Treated group</arm_group_label>
    <other_name>Parachute Device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at least 18 years of age with symptoms of heart failure and anteroapical wall
        motion abnormality due to myocardial infarction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post MI structural heart dysfunction represented by left ventricular (LV) wall motion
             abnormality (WMA)

          -  Symptomatic Heart Failure with reduced Ejection Fraction (EF) (≤ 40%)

          -  Receiving stable medication for heart failure according to the European Society of
             Cardiology (ESC) Heart Failure (HF) Guidelines

          -  &gt;18 years of age

          -  Provide written informed consent

          -  Agree to the protocol-required follow-up

        Exclusion Criteria:

          -  Acute myocardial infarction (MI) of the left anterior descending territory within 90
             days of enrollment or patients with suspected evolving MI at time of enrollment

          -  Cardiogenic shock within 72 hours of enrollment

          -  A known hypersensitivity or contraindication to aspirin, warfarin, nitinol (titanium
             and nickel alloy), or sensitivity to contrast media, which cannot be adequately pre
             medicated

          -  Other hemodynamically structural heart interventions or heart failure device treatment
             at time of Parachute implant, e.g. mitral valve clip or cardiac resynchronization
             therapy).

          -  Co-morbidities associated with a life expectancy of less than 12-months

          -  Treatment Arm only (Control Arm excluded from this criteria): Anatomical
             characteristics not suitable for treatment with the Parachute Implant device as
             screened by magnetic resonance imaging (MRI) or computerized tomography (CT).
             (Characteristics include inappropriate size and shape of the left ventricle, pseudo
             chordae or trabeculations interfering with device placement.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helge Möllmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac Research GmbH</name>
      <address>
        <city>Dortmund</city>
        <state>Hohe Straße 1</state>
        <zip>Dortmund</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Essen, Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Essen</city>
        <state>Klara-Kopp-Weg 1</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Kardiologie, Pneumologie und Angiologie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Moorenstr. 5</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik gGmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfalkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. George</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg Eppendorf GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>parachute</keyword>
  <keyword>partitioning device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

